Senate Republicans to challenge auto safety mandates in January - WSJ
SOUTH SAN FRANCISCO - Twist Bioscience Corporation (NASDAQ:TWST) shares fell 9% after the biotech company reported a wider-than-expected loss for its fourth quarter, despite beating revenue expectations.
The company reported a fourth quarter loss of -$0.45 per share, missing analyst estimates of -$0.41, even as revenue came in at $99 million, surpassing the consensus estimate of $97.21 million. The quarterly revenue represented a 17% increase compared to the $84.7 million reported in the same period last year.
Twist’s shares tumbled following the earnings release as investors focused on the company’s continued losses despite revenue growth. The company reported gross margin of 51.3% for the quarter, an improvement from 45.1% in the same period last year.
"We ended the fiscal year with record revenue in the fourth quarter exceeding our guidance. By leveraging our technology, commercial execution and meeting the needs of our customers, we expanded our customer base and grew revenue 20% for the full fiscal year compared to the year prior," said Emily M. Leproust, CEO and co-founder of Twist Bioscience.
For fiscal 2026, Twist expects total revenue between $425 million and $435 million, representing growth of 13% to 15.5% YoY. The company also anticipates gross margin to remain above 52% for fiscal 2026 and aims to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026.
The company shipped products to approximately 3,800 customers in fiscal 2025, up from 3,550 in fiscal 2024, and delivered approximately 938,000 genes during the year, compared to 772,000 in the previous fiscal year.
For the first quarter of fiscal 2026, Twist expects revenue of $100 to $101 million, representing growth of approximately 13% to 14% compared to the first quarter of fiscal 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.